Bmi1 knockdown inhibits hepatocarcinogenesis

International Journal of Oncology

Volumn 42, Issue 1, 2013, Pages 261-268

  Ruan, Zhi Ping ^a   Xu, Rui ^a,b   Lv, Yi ^a   Tian, Tao ^a   Wang, Wen Juan ^a   Guo, Hui ^a   Nan, Ke Jun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Shaanxi Cancer Hospital   (China)

Author keywords

Bmi1; Hepatocellular carcinoma; Proliferation; Sorafenib

Indexed keywords

BMI1 PROTEIN; SHORT HAIRPIN RNA; SORAFENIB;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CARCINOGENICITY; CELL CYCLE CHECKPOINT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 7; NEOPLASM STAGING; PROGNOSIS; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84873676907     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1693     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001. (Pubitemid 32911406)
2. Bertolini G, Roz L, Perego P, et al: Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106: 16281-16286, 2009.
3. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997. (Pubitemid 27298715)
4. Uchida N, Buck DW, He D, et al: Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 97: 14720-14725, 2000. (Pubitemid 32016642)
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. (Pubitemid 36418143)
6. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007. (Pubitemid 46067311)
7. Rountree CB, Ding W, He L and Stiles B: Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells 27: 290-299, 2009.
8. Van der Lugt NM, Domen J, Linders K, et al: Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev 8: 757-769, 1994.
9. Pirrotta V: Polycombing the genome: PcG, trxG, and chromatin silencing. Cell 93: 333-336, 1998. (Pubitemid 28232078)
10. Kranc KR, Bamforth SD, Braganca J, Norbury C, van Lohuizen M and Bhattacharya S: Transcriptional coactivator Cited2 induces Bmi1 and Mel18 and controls fibroblast proliferation via Ink4a/ARF. Mol Cell Biol 23: 7658-7666, 2003. (Pubitemid 37271464)
11. Saito M, Handa K, Kiyono T, et al: Immortalization of cementoblast progenitor cells with Bmi-1 and TERT. J Bone Miner Res 20: 50-57, 2005. (Pubitemid 41716218)
12. Kim JH, Yoon SY, Kim CN, et al: The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203: 217-224, 2004. (Pubitemid 38058689)
13. Sasaki M, Ikeda H, Itatsu K, et al: The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 88: 873-882, 2008.
14. Vrzalikova K, Skarda J, Ehrmann J, et al: Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol 134: 1037-1042, 2008.
15. Park IK, Qian D, Kiel M, et al: Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423: 302-305, 2003. (Pubitemid 40852701)
16. Lessard J and Sauvageau G: Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255-260, 2003. (Pubitemid 40852690)
17. Liu S, Dontu G, Mantle ID, et al: Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66: 6063-6071, 2006.
18. Chiba T, Seki A, Aoki R, et al: Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf-dependent and -independent manners in mice. Hepatology 52: 1111-1123, 2010.
19. Glinsky GV: Stem cell origin of death-from-cancer phenotypes of human prostate and breast cancers. Stem Cell Rev 3: 79-93, 2007. (Pubitemid 47472815)
20. Wang H, Pan K, Zhang HK, et al: Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 134: 535-541, 2008. (Pubitemid 351422607)
21. Zhang Y, Li B, Ji ZZ and Zheng PS: Notch1 regulates the growth of human colon cancers. Cancer 116: 5207-5218, 2010.
22. Tomuleasa C, Soritau O, Rus-Ciuca D, et al: Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis 19: 61-67, 2010.
23. Zhu Z, Hao X, Yan MX, et al: Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 126: 2067-2078, 2010.
24. Leung C, Lingbeek M, Shakhova O, et al: Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428: 337-341, 2004. (Pubitemid 38418806)
25. Vonlanthen S, Heighway J, Altermatt HJ, et al: The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84: 1372-1376, 2001. (Pubitemid 32522106)
26. Kim JH, Yoon SY, Jeong SH, et al: Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 13: 383-388, 2004. (Pubitemid 39549787)
27. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM and Glinsky GV: Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 5: 1886-1901, 2006. (Pubitemid 44435335)
28. Qin ZK, Yang JA, Ye YL, et al: Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer 9: 61, 2009.
29. Glinsky GV, Berezovska O and Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503-1521, 2005. (Pubitemid 40814659)
30. Chiba T, Miyagi S, Saraya A, et al: The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res 68: 7742-7749, 2008.
31. Cui H, Hu B, Li T, et al: Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 170: 1370-1378, 2007. (Pubitemid 47339343)
32. Bruggeman SW, Hulsman D, Tanger E, et al: Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 12: 328-341, 2007. (Pubitemid 47539307)
33. Yu CC, Lo WL, Chen YW, et al: Bmi-1 regulates Snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1 positive cells. J Oncol 2011: pii: 609259, 2011.
34. Park IK, Morrison SJ and Clarke MF: Bmi1, stem cells, and senescence regulation. J Clin Invest 113: 175-179, 2004. (Pubitemid 38544200)
35. Dimri GP, Martinez JL, Jacobs JJ, et al: The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 62: 4736-4745, 2002.
36. Jane EP, Premkumar DR and Pollack IF: Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther 319: 1070-1080, 2006.
37. Yu C, Friday BB, Lai JP, et al: Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther 5: 2378-2387, 2006. (Pubitemid 44530475)